Hook & thesis
HealthEquity is doing the things that move its economics: account growth, accelerating invested balances and meaningful free cash flow conversion. Investors have punished the stock in the past for security scares and lumpy guidance, but the most recent cadence of results and operating metrics argues that core fundamentals are improving and that earnings momentum is not getting full credit from the market.
That creates a trade opportunity. My thesis: buy a tactical long at roughly $95 with a defined stop and a target near $110 over the next 45 trading days. The trade leans on continued HSA asset expansion, higher share of invested balances and ongoing margin leverage — all of which have translated to outsized net income improvement in recent quarters. Valuation is not cheap, but it is supportable given free cash flow and growth in invested assets.
What HealthEquity does and why the market should care
HealthEquity is the largest HSA custodian in the U.S., providing technology-enabled services that help individuals and employers manage health spending. The key revenue and profit levers are: (1) new HSA account sales and total account growth, (2) HSA assets and the percent invested versus cash, and (3) fee yield on assets plus platform/service revenue and operating leverage.
Why this matters: money held in HSAs — especially the portion that is invested — creates recurring asset-based revenue and drives higher margin economics. When invested balances grow faster than total deposits, the company benefits from higher fee yield and better FCF conversion.
What’s backing the bullish take — the numbers
- Account growth: HSAs increased 7% to 10.6 million accounts, while total accounts reached 17.8 million.
- Assets under custody: HSA assets rose 14% to $36.5 billion.
- Investment adoption: HSA investments grew 26% to $18.5 billion — this is the highest-margin portion of the balance sheet.
- Profitability: the company reported a 67% jump in net income in a strong Q2 and has delivered consistent operating leverage across fiscal 2026; EPS on the latest snapshot is $2.76 and trailing P/E sits around 34x.
- Free cash flow: FCF is sizeable at roughly $457.2 million, giving the business financial flexibility and a valuation multiple that can be supported by cash generation.
These are not small numbers. The combination of account adds (more users), more assets (higher base to charge fees on) and a rising share of invested balances increases recurring revenue and improves margins over time.
Valuation framing
Market cap sits roughly at $7.9 billion with enterprise value around $8.59 billion. On the common metrics the company trades at about 34x earnings, EV/sales near 6.4x and EV/EBITDA about 17x. Those multiples look full when judged against broad-market software names, but HealthEquity is a hybrid: it earns asset-based fees (sticky, annuity-like) and benefits from the long-duration economics of HSA investing.
Two points on valuation logic:
- Free cash flow supports the multiple. With FCF near $457M, investors are essentially paying roughly 17-19x FCF — a multiple that is not crazy for a high-quality, cash-generative fintech with growth in invested assets.
- The market currently prices some execution risk into HQY (and historically security incidents have dented sentiment). If the company continues to show steady HSA sales and further lifts invested balances, multiples can re-rate modestly without needing explosive revenue growth.
Catalysts to drive the trade higher (2-5)
- Quarterly results that beat or reaffirm guidance: the company reaffirmed guidance for fiscal 2026 and 2027 and reported record Q4 sales (02/17/2026). A clean beat or continued positive cadence will force re-rating.
- Invested-balance growth continuing above trend: if invested assets keep rising faster than total HSA balances (recently +26% year-over-year to $18.5B), the revenue mix improves and margins expand.
- Sales momentum in new HSAs: record fourth-quarter new HSA sales and more than one million new HSA accounts added during the fiscal year (02/17/2026) indicate conversion funnels are healthy — continued strong sales will matter to forward revenue visibility.
- Positive research or industry headlines emphasizing the HSA value proposition, such as work-force savings studies (06/08/2026), could lift sentiment and user growth simultaneously.
Trade plan (actionable)
Direction: Long
Entry price: $94.91
Stop loss: $88.00
Target: $110.00
Horizon: mid term (45 trading days) — I expect this trade to play out over the next 45 trading days because catalysts (quarterly results confirmation, further evidence of invested-balance growth and short-covering) should materialize in that window. If the position arcs toward the target earlier, trim exposure and lock gains; if it fails to show momentum after ~30 trading days, re-evaluate and consider an orderly exit.
Rationale: entry near $94.91 lines up with the recent trading range (10-day SMA $96.32, 20-day SMA $94.74, 50-day SMA $89.77). A stop at $88 sits below the 50-day average and provides a clear technical level where momentum and mean-reversion would look broken. The $110 target implies roughly a 16% upside from entry — reasonable given a re-rating toward the prior 52-week high of $105.96 and upside if invested balances accelerate and margins improve further.
Execution notes
- Position sizing should reflect the stop-loss (risk per share ≈ $6.91). Keep trade risk at a small percentage of portfolio capital — this is a tactical swing, not a core buy-and-hold position.
- Be alert for news flow around security incidents or legal headlines that have previously driven outsized moves; these can invalidate the thesis quickly.
- Use partial profit-taking: consider selling half at $102 and the rest at $110 or trailing the stop to protect gains.
Risks and counterarguments
- Security and fraud risk: past incidents and elevated criminal activity headlines materially impact sentiment and could cause outsized share-price moves irrespective of fundamentals. Litigation or further breaches would be a direct negative.
- Valuation sensitivity: at ~34x earnings, the stock is priced for continued execution. If revenue growth slows or margins compress, multiples could retrace quickly.
- Sales cadence risk: organic HSA sales have shown some variability historically. If new-account growth slips, the revenue base risks re-acceleration and investor confidence may wane.
- Macro/market risk: a broader sell-off in growth/fintech stocks could drag HQY down even with steady fundamentals — liquidity and sentiment matter for this trade's timeframe.
- Short interest & volatility: short interest has been non-trivial at times; while that can fuel rallies, it also contributes to choppy trading and higher intraday volatility, which can hit stop levels before the thesis plays out.
Counterargument: One could argue the company is already fairly valued given its P/E and EV multiples and that most of the near-term upside is priced in. If management cannot sustain invested-balance growth or if they guide conservatively on fees, the stock could languish or drift lower even with decent underlying metrics. That is a valid view and is why the recommended trade is tactical with a strict stop.
Conclusion and what would change my mind
My stance: constructive tactical long. HealthEquity’s account and invested-balance dynamics give it durable earnings leverage that the market has underappreciated. The combination of sizable FCF (about $457M), account growth (10.6M HSAs; 17.8M total accounts) and accelerating investments (up 26% to $18.5B) supports a mid-term re-rating, provided management continues to execute and avoids headline-driven shocks.
What would change my mind: evidence of a new or unresolved security breach, a material slowdown in new HSA sales, or guidance that meaningfully reduces expected invested-balance growth would all force a reassessment and likely result in closing the position. Conversely, sustained beats, faster-than-expected invested-balance growth, or a marked improvement in fee yield would make me upgrade the trade to a larger position or extend the horizon.
Trade idea recap: Long HQY at $94.91, stop $88.00, target $110.00, mid-term horizon (45 trading days). Risk managed with tight stop and partial profit-taking.
Key historical touchpoints (for context)
- 02/17/2026 - Strong fiscal 2026 results: HSAs at 10.6M, total accounts 17.8M, HSA assets $36.5B and HSA investments $18.5B.
- 09/03/2025 - Q2 fiscal 2026: reported 9% revenue growth and a 67% jump in net income.
- 06/08/2026 - Survey and research showing the value of HSAs to workers and employers, which can support demand for HSA solutions.